Your browser doesn't support javascript.
loading
Drugs and drug delivery strategies for treatment of pulmonary arterial hypertension / 药学学报
Acta Pharmaceutica Sinica ; (12): 1332-1342, 2021.
Article in Zh | WPRIM | ID: wpr-887076
Responsible library: WPRO
ABSTRACT
Pulmonary arterial hypertension (PAH), also named as a cancer of cardiovascular disease, is a rare disease and has complicated pathogenesis. Recently, there are more understandings of PAH pathogeneses. According to the pathogenesis and active pathways, the clinically used drugs are classified into several groups incluidng prostacyclin analogues and prostacyclin receptor agonists, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase inhibitors, etc. To elevate the efficacy of the drugs, numerous drug delivery systems are developed. This review mainly summarized the pathological mechanism of PAH, drugs and drug delivery approaches in the treatment of PAH.
Key words
Full text: 1 Index: WPRIM Language: Zh Journal: Acta Pharmaceutica Sinica Year: 2021 Type: Article
Full text: 1 Index: WPRIM Language: Zh Journal: Acta Pharmaceutica Sinica Year: 2021 Type: Article